Designed for pulmonary vein isolation (PVI), the Medtronic cryoballoon ablation system offers an anatomical approach to addressing atrial arrhythmias, creating wide antral, contiguous circumferential lesions surrounding the target anatomy.
The Arctic Front™ cryoablation system is the leader in cryoballoon technology with over 17 years of clinical experience, treating more than one million patients worldwide.1
Arctic Front Advance™ and Arctic Front Advance Pro™ enable safe effective, and efficient procedures. The Arctic Front™ system provides physicians with a straightforward approach to PVI with minimal applications, durable lesions, and delivering consistent and predictable results,2 for first-line, paroxysmal, and persistent AF patients.3–6
The Medtronic cryoablation system includes the Freezor™ family of cryoablation catheters, which include devices approved for the treatment of AF or pediatric and adult AVNRT.12,13
The Medtronic Arctic Front™ cryoballoon system is the only ablation system FDA-approved as an initial rhythm control strategy for patients with paroxysmal atrial fibrillation. It is also indicated for the treatment of paroxysmal and persistent† AF patients.
Meta-analysis of three randomized first-line trials, STOP AF First, EARLY-AF, and Cryo-FIRST, demonstrates cryoablation is more effective than antiarrhythmic drugs as an initial first-line therapy for patients with paroxysmal AF.14
Access detailed product information, including specification sheets, videos, and presentations.
Phone: 877-464-2796
The Achieve™ mapping catheter enables the assessment of pulmonary vein isolation during cryoablation procedures.
The FlexCath Advance™ steerable sheath is used to position an ablation catheter during atrial fibrillation procedures.
The FlexCath Contour™ steerable sheath provides enhanced maneuverability during atrial fibrillation ablation procedures.
The Nitron CryoConsole™ cardiac cryoablation system houses electrical and mechanical components as well as software used for cryotherapy procedures.
† Indicated for symptomatic persistent AF defined as a continuous, sustained episode lasting longer than seven days but less than or equal to six months.